Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy.
View/ Open
Date
2016-05-15Author
Somaiah, N
Chua, MLK
Bourne, S
Daley, F
A' Hern, R
Nuta, O
Gothard, L
Boyle, S
Herskind, C
Pearson, A
Warrington, J
Helyer, S
Owen, R
Rothkamm, K
Yarnold, J
Type
Journal Article
Metadata
Show full item recordAbstract
AIM: To correlate residual double strand breaks (DSB) 24h after 4Gy test doses to skin in vivo and to lymphocytes in vitro with adverse effects of earlier breast radiotherapy (RT). PATIENTS AND METHODS: Patients given whole breast RT ⩾5years earlier were identified on the basis of moderate/marked or minimal/no adverse effects despite the absence ('RT-Sensitive', RT-S) or presence ('RT-Resistant', RT-R) of variables predisposing to late adverse effects. Residual DSB were quantified in skin 24h after a 4Gy test dose in 20 RT-S and 15 RT-R patients. Residual DSB were quantified in lymphocytes irradiated with 4Gy in vitro in 30/35 patients. RESULTS: Mean foci per dermal fibroblast were 3.29 (RT-S) vs 2.80 (RT-R) (p=0.137); 3.28 (RT-S) vs 2.60 (RT-R) in endothelium (p=0.158); 2.50 (RT-S) vs 2.41 (RT-R) in suprabasal keratinocytes (p=0.633); 2.70 (RT-S) vs 2.35 (RT-R) in basal epidermis (p=0.419); 12.1 (RT-S) vs 10.3 (RT-R) in lymphocytes (p=0.0052). CONCLUSIONS: Residual DSB in skin following a 4Gy dose were not significantly associated with risk of late adverse effects of breast radiotherapy, although exploratory analyses suggested an association in severely affected individuals. By contrast, a significant association was detected based on the in vitro response of lymphocytes.
Collections
Subject
Breast
Lymphocytes
Skin
Humans
Breast Neoplasms
Radiotherapy Dosage
Aged
Aged, 80 and over
Middle Aged
Female
DNA Breaks, Double-Stranded
Research team
Translational Breast Radiobiology
Language
eng
Date accepted
2016-04-09
License start date
2016-05
Citation
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016, 119 (2), pp. 244 - 249
Publisher
ELSEVIER IRELAND LTD